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Abstract Pre-clinical studies of renal denervation would
suggest that the extent of renal nerve injury correlates with
outcomes. The ‘‘completeness’’ of renal nerve injury fol-
lowing renal denervation correlates with treatment-based
variables such as the depth of ablation, the number of abla-
tions along the length of the artery, and the number of renal
arteries successfully ablated. Renal denervation techniques
targeting only main renal arteries may lead to suboptimal
results in patients with accessory renal artery anatomy.
Technological differences among the different systems may
make some more suited for this common anatomical variant.
The early clinical experience with renal denervation of
accessory renal arteries highlights the importance of com-
plete renal denervation for clinical success.
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Renal denervation targets the sympathetic nerves located in
the adventitia of the renal artery wall [1]. The nerves travel
from the spinal cord along the artery and then to the kidney
where extensive branching occurs. Pre-clinical studies
would suggest that the degree of renal nerve injury corre-
lates with outcomes (Mazor M. Efficacy of renal dener-
vation is positively impacted by longitudinal treatments,
TCT 2012, October 22–26, Miami, FL). Yet it is unlikely
that complete denervation of the entire renal sympathetic
nervous system is achieved with any renal artery ablation
technology available. Variables such as the depth of abla-
tion into the renal artery wall, the number of ablations
along the length of the artery, and the number of renal
arteries successfully ablated all correlate with the ‘‘com-
pleteness’’ of renal nerve injury and may affect clinical
outcomes.
Hypertensive patients with accessory renal arteries who
undergo renal denervation highlight the issue of whether
complete interruption of the renal sympathetic nervous
system correlates with changes in blood pressure. Most
clinical trials of renal denervation have excluded patients
with accessory renal arteries [2–6], yet these patients may
constitute as much as 27 % of the resistant hypertension
population [7]. Id and colleagues recently reported their
results of renal denervation using the Symplicity catheter
system (Medtronic, Santa Rosa, CA) in patients both with
and without accessory renal arteries [8]. The drop in office-
based systolic blood pressure (SBP) at 6 months was sig-
nificantly less in the patients with accessory renal arteries
compared to those with only main renal artery trunks (-6.2
vs -16.6 mmHg, p = 0.027). The patients with accessory
renal arteries were further subdivided into two groups: (1)
those in whom all accessories underwent successful
denervation and (2) those in whom only some or no
accessory renal arteries could be denervated. The subgroup
with complete accessory renal artery denervation experi-
enced a slightly greater drop in SBP compared to patients
with incomplete treatment of their accessory arteries (-8.8
vs -4.1 mmHg).
Since the majority of renal nerves terminate at vascular
structures within the kidney [9], nerve traffic to and from
the kidney likely corresponds to the blood supply, traveling
with both accessory and main renal arteries. So patients
with accessory renal arteries may fail to respond if treated
with a denervation technique targeting nerves only in the
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main renal artery—just as was observed by Id and col-
leagues [8]. Yet why, in their study, was the blood pres-
sure-lowering response in the subgroup with ‘‘complete’’
denervation of accessory renal arteries less than that in the
group with only main renal artery trunks (Fig. 1a)? This
difference may in part be explained by limitations of the
Symplicity renal denervation system for ablation of
accessory renal arteries. The Symplicity system is com-
posed of a single electrode monopolar radiofrequency
ablation catheter connected to an automated generator.
Energy passes from the generator through the catheter to an
external grounding pad, which serves as a far field elec-
trode. The generator delivers up to 8 W of power to the
catheter tip causing heating of the adjacent tissue and
consequent nerve injury. The system avoids overheating of
the tissue by monitoring temperature from a thermistor
near the electrode tip, shutting off power if the temperature
exceeds a predetermined threshold. Cooling of the catheter
tip from renal blood flow is critical to avoid overheating. In
low-flow conditions with inadequate cooling, the generator
will terminate energy delivery to prevent excessive tissue
damage. Ablation will be interrupted, and denervation
efficiency potentially compromised.
Accessory renal arteries can present a low-flow condi-
tion with limited cooling from the bloodstream. Renal
denervation systems such as Symplicity that require cool-
ing may not be well-suited for the treatment of accessory
renal arteries due to insufficient cooling from lower blood
flow. By contrast, the Vessix Renal Denervation System
(Boston Scientific Corporation, Natick, MA) does not
require cooling from the bloodstream; its design integrates
multiple elements that make cooling unnecessary. First, it
delivers energy to the tissue via pairs of bipolar electrodes
(Fig. 2) with efficient energy transfer leading to short
treatment times. Second, the Vessix System controls tem-
perature at 68 C so that overheating cannot occur. Tem-
perature control is enabled by a thermistor located between
the positive and negative poles of each electrode pair
(Fig. 2). And finally, the electrodes and thermistors are all
mounted on a balloon catheter (Fig. 2). When inflated, the
balloon apposes the electrodes and thermistors to the renal
artery wall and simultaneously obstructs blood flow down
Fig. 1 Reduction in office-based systolic BP 6 months following
renal denervation treatment––Black bars represent patients without
accessory renal arteries who had renal denervation treatment. Gray
bars represent patients with ‘‘complete’’ treatment of accessory renal
arteries (as defined by Id et al. [8]). a Reductions following treatment
with the Symplicity system [8]. b Reductions following treatment with
the Vessix System (Sievert H. REDUCE-HTN Clinical Study Interim
6 and 12 months data. TCT 2013. San Francisco, October 28, 2013)
Fig. 2 Illustration of the helical array of bipolar electrodes (electrode
pair indicated with arrowheads) and thermistors (arrow) mounted on
the Vessix balloon catheter. Used with permission of Boston
Scientific Corporation 2014 Boston Scientific Corporation or its
affiliates. All rights reserved
682 Clin Res Cardiol (2014) 103:681–683
123
the artery so that the thermistor readings provide a close
approximation of tissue temperature without interference
from the cooling effects of the bloodstream. All of these
design elements combine into a denervation system that
functions independent of blood flow conditions; and with
catheter sizes suited for arteries as small as 3 mm in
diameter, the Vessix device is optimized for renal dener-
vation of accessory arteries.
The REDUCE-HTN post-market study tested the Vessix
System in patients with resistant hypertension, including 24
patients with accessory renal arteries. In this subgroup
where accessory renal arteries were treated, SBP dropped
by -21.0 mmHg at 6 months (Sievert H. REDUCE-HTN
Clinical Study Interim 6 and 12 months data, TCT 2013.
San Francisco, October 28, 2013). In the absence of a direct
head-to-head trial, these results cannot be fairly compared
to those reported by Id and colleagues [8] (Fig. 1a, b), yet
with one system the presence of accessory renal arteries
appears to compromise efficacy while efficacy seems pre-
served with the other. The Vessix technology may result in
more complete renal nerve injury despite variant renal
artery anatomy.
The importance of denervation technology for complete
renal nerve ablation cannot be overstated in light of the
Symplicity HTN3 trial failure to meet its primary efficacy
endpoint [10]. In the successful predicate studies to HTN3,
namely HTN1 and HTN2, a catheter with a fixed distal curve
(Arch) enabling renal artery wall apposition was replaced in
HTN3 with a catheter (Flex) requiring operator manipula-
tion for vessel wall contact. Less consistent catheter contact
with the renal artery wall diminishes ablation effectiveness.
The newer technology may have resulted in less renal nerve
injury compromising the clinical trial results. It will be
critical to understand whether these differences in renal
denervation technologies lead to different degrees of nerve
injury and translate into variations in clinical outcomes.
Complete renal denervation should be the goal.
Acknowledgments I thank Margaret Taber and Elizabeth Davis
(Boston Scientific Corporation, Marlborough, MA) for assistance with
figure preparation and with preparing the manuscript for submission.
Disclosure Consulting fees have been received from Medtronic and
Boston Scientific/Vessix. No funding was received for preparing this
work; open access was funded by Boston Scientific Corporation.
References
1. Atherton DS, Deep NL, Mendelsohn FO (2012) Micro-anatomy
of the renal sympathetic nervous system: a human postmortem
histologic study. Clin Anat 25:628–633
2. Krum H, Schlaich M, Whitbourn R (2009) Catheter-based renal
sympathetic denervation for resistant hypertension: a multicentre
safety and proof-of-principle cohort study. Lancet 373:1275–
1281
3. Symplicity HTN-2 Investigators (2010) Renal sympathetic
denervation in patients with treatment resistant hypertension (the
Symplicity HTN-2 Trial): a randomized controlled trial. Lancet
376:1903–1909
4. Kandzari DE, Bhatt DL, Sobotka PA et al (2012) Catheter-based
renal denervation for resistant hypertension: rationale and design
of the SYMPLICITY HTN-3 Trial. Clin Cardiol 35:528–535
5. Vogel B, Kirchberger M, Zeier M et al (2014) Renal sympathetic
denervation therapy in the real world: results from the Heidelberg
registry. Clin Res Cardiol 103:117–124
6. Mahfoud F, Luscher TF, Andersson B et al (2013) Expert con-
sensus document from the European Society of Cardiology on
catheter-based renal denervation. Eur Heart J 34:2149–2157
7. Satyapal KS, Haffejee AA, Singh B, Ramsaroop L, Robbs JV,
Kalideen JM (2001) Additional renal arteries: incidence and
morphometry. Surg Radiol Anat 23:33–38
8. Id D, Kaltenbach B, Bertog SC et al (2013) Does the presence of
accessory renal arteries affect the efficacy of renal denervation?
J Am Coll Cardiovasc Interv 6:1085–1091
9. Barajas L, Powers K (1990) Monoaminergic innervation of the
rat kidney: a quantitative study. Am J Physiol 259:F503–F511
10. Press release (2014) Medtronic announces U.S. renal denervation
pivotal trial fails to meet primary efficacy endpoint while meeting
primary safety endpoint. http://newsroom.medtronic.com/phoe
nix.zhtml?c=251324&p=irol-newsArticle&id=1889335. Accessed
04 March 2014
Clin Res Cardiol (2014) 103:681–683 683
123
